Controversies in the use of beta blockers in heart failure. Increasingly, the cardiac sympathetic nervous system sns is being. Mar 29, 2011 heart failure is a major public health concern that is frequently complicated by ventricular arrhythmias. Reply journal of the american college of cardiology. Cibis ii results will represent a basis for definite conclusions on the evaluation of betaadrenoceptor blockade induced benefit with bisoprolol in chronic heart failure. Based on recommended initial starting and target doses of these 2 betablockers in the various clinical trials cibis ii, us carvedilol studies, 12 and copernicus, 11 and the clinical pharmacy practice guidelines for hf patients developed by singapore ministry of health, 7 we decided on a 5. A randomized trial of betablockade in heart failure. Background underrepresentation of women in hf clinical trials has limited our understanding of genderrelated differences in patients with. Baseline heart rate was higher in the carvedilol group 822 bpm vs.
What is the best betablocker mountain area health for. The mean age of patients in the study was 73 years and 38% were women. Les betabloqueurs dans linsuffisance cardiaque revue medicale. Clinical trials update from the esc heart failure meeting 2009. Hf, the cardiac insufficiency bisoprolol study ii cibis. Cibis ii was stopped early, after the second interim analysis, because bisoprolol showed a significant mortality benefit. We summarize the current management strategies for ventricular tachycardia in heart failure patients, including implantable cardioverterdefibrillator therapy. Ibis ii was designed to continue the work started in ibisi by examining the role of anastrozole in the prevention of breast cancer which we hope will reduce breast cancer by even more than tamoxifen with less serious side effects. Interpretation of these data is the responsibility of the authors, and in no way should be seen as an official policy or interpretation of the u. Merithf and cibis ii trials, the placebo mortality rate and the mortality risk reduction of metoprolol and bisoprolol are similar to that achieved by carvedilol in copernicus. Impact of a standardized heart failure order set on mortality. Betaadrenergic blocker mortality trials in congestive heart failure. The page includes a summary of phase iii clinical trials, an overview of indications under investigation by the different drugs and helpful services for patients and healthcare professionals. Selective versus nonselective adrenergic receptor blockade.
Usrds waves 3 and 4 study11the data reported here were supplied by the united states renal data system. In race ii trial, goal resting hr jan 28, 2009 recently, the carvedilol or metoprolol european trial comet, 8 a double. Listing a study does not mean it has been evaluated by. The mortality benefit of lowdose beta blockade in congestive heart failure is encouraging.
It is designed to determine whether hibernating myocardium andor inhomogeneity of sympathetic innervation by positron emission tomography imaging identifies patients with ischemic cardiomyopathy who are at high risk for scd and cardiovascular mortality. Sustained ventricular tachycardia is associated with an increased risk for progressive heart failure and sudden death. Allcause mortality was significantly lower with bisoprolol than on placebo 156 11. Therapeutic interchange of carvedilol to bisoprolol for. The results of cibis ii were reported at the second annual scientific meeting of the heart failure society of america that should influence physician practice in the care of patients with left ventricular dysfunction and heart failure. Data for total hospitalizations are shown in table ii. Objectives the goal of this study was to determine the influence of gender on baseline characteristics, response to treatment, and prognosis in patients with heart failure hf and impaired left ventricular ejection fraction lvef. The first of these trials is the cardiac insufficiency bisoprolol study cibis i. Prediction of arrhythmic events with positron emission. Background underrepresentation of women in hf clinical trials has limited our understanding of genderrelated differences in patients with hf. Eula suiteplus trial for sql server 2008, 2012, 2014, 2016. Nyha class iii and iv hf patients n2,647 with lvef cibis ii study to evaluate bisoprolol for allcause mortality.
Cibis iii was an investigatorinitiated, multicenter trial that compared the effects on mortality and hospitalization of initial monotherapy with either bisoprolol or enalapril for 6 months. Listing a study does not mean it has been evaluated by the u. All decisions regarding this manuscript were made by a guest editor. Pdf background in patients with heart failure, betablochade has improved morbidity and leftventricular function, but the impact on survival is. We aim to provide an overview of the conventional single photon emission computed tomography spect and emerging positron emission tomography pet catecholamine analogue tracers for assessing myocardial nerve integrity, in particular focusing on 18flabeled tracers. Pdf the cardiac insuffiency bisoprolol study ii cibis ii. The trial was stopped prematurely at the second interim analysis because of positive results in the beta blocker arm. Release randomized intervention trial in heart failure merit. A free powerpoint ppt presentation displayed as a flash slide show on id. This study aimed to analyze the degree of concordance between targeted cibis ii. Functional benefit in heart failure due to idiopathic dilated cardiomyopathy has been observed after betablockade, but improvement in survival has not been established in a largescale randomized trial. The cardiac insufficiency bisoprolol study ii cibis ii. Apr 01, 2008 heart failure caused by systolic dysfunction affects more than 5 million adults in the united states and is a common source of outpatient visits to primary care physicians. Methods the study design and protocol of cibis has been published.
Ibis ii prevention research has shown that anastrozole is more effective than tamoxifen in preventing the return of cancer in postmenopausal women who have an early breast cancer removed. The benefits of beta blockers in heart failure are highly dependent on dosage. The safety of amiodarone in patients with heart failure. Ekman m, zethraeus n, jonsson b 2001 cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in sweden. Metoprolol tartrate pharmacokinetics absorption bioavailability. Pharmacologic management of heart failure caused by. Colucci ws, packer m, bristow mr et al, for the us carvedilol heart failure study group. This website is a free of charge service from daiichi sankyo europe gmbh.
The cardiac insufficiency bisoprolol study cibisii which was a randomized trial of hf patients with left ventricular ejection fraction. Simon, md, march 2001, and simon et al10 with epiinfo version 6. Despite clinical trials demonstrating that inhibitors of the renin. This was the main objective of the cardiac insufficiency bisoprolol study cibis. Allcause mortalityallcause hospitalisationssuddendeath. Treatment of ventricular tachycardia in patients with heart. Heart failure caused by systolic dysfunction affects more than 5 million adults in the united states and is a common source of outpatient visits to primary care physicians. Pooling of total mortality data by sex and overall from cibis ii,2 merithf,3 and copernicus5 was performed with a metaanalysis technique based on the 95% cis of the relative risks in the studies. Metoprolol tartrate is rapidly and almost completely absorbed from the gi tract.
New heart failure clinical trial 19981129 ahc media. Parepet is a prospective, observational cohort study funded by nhlbi. Cibis ii was the first randomized controlled trial with sufficient power to address all cause mortality as a primary objective. All patients had new york heart association functional class ii or iii symptoms. Metoprolol crxl in female patients with heart failure. Total heart failure direct costs were estimated as part of a threestep process. Pharmacologic management of heart failure caused by systolic.
Only 219 patients 25% achieved smooth titration to the target dose without the need to delay increases or reduce the dose. Bisoprolol doseresponse relationship in patients with congestive. A comparative analysis of the results from 4 trials of. May 01, 2014 trial of s1 maintenance therapy in metastatic esophagogastric cancer mateo the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. There were no other significant differences in baseline systemic or pulmonary hemodynamics between the two groups. The cardiac insufficiency bisoprolol study ii cibisii. New heart failure clinical trials 19981101 ahc media. In cibis ii, which was a doubleblind trial that randomized 2647 patients with symptomatic nyha class iii or iv hf and lvef. Bisoprolol doseresponse relationship in patients with congestive heart failure. Trial of s1 maintenance therapy in metastatic esophagogastric cancer mateo the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. In these women it reduces their risk of developing a new cancer in the opposite contralateral breast by 53% compared to tamoxifen 1. The merithf trial demonstrated that treatment with metoprolol crxl resulted in. Cibisii was stopped early, after the second interim analysis, because bisoprolol showed a significant mortality benefit.
515 150 796 939 1205 127 1546 1330 360 1050 1463 416 1657 429 237 1614 895 1233 1580 830 1453 337 691 808 508 418 1237